NeuroDerm Company Profile (NASDAQ:NDRM)

About NeuroDerm

NeuroDerm logoNeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa/carbidopa (LD/CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, which is for the treatment of patients suffering from severe Parkinson's disease; ND0612L, which is for the treatment of patients at the moderate stage of Parkinson's disease, and ND0701, which is an apomorphine-based product. The Company is also developing a product candidate, ND0801, to treat cognition disorders associated with CNS diseases. The Company's delivery devices include CRONO ND, which is a fixed-dose belt pump, and CRONO Twin ND, which is an adjustable belt pump.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NDRM
  • CUSIP:
Key Metrics:
  • Previous Close: $23.35
  • 50 Day Moving Average: $23.50
  • 200 Day Moving Average: $19.55
  • 52-Week Range: $11.83 - $25.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.50
  • P/E Growth: 0.00
  • Market Cap: $507.16M
  • Outstanding Shares: 21,720,000
  • Beta: 0.94
Profitability:
  • Return on Equity: -32.12%
  • Return on Assets: -30.45%
Debt:
  • Current Ratio: 15.77%
  • Quick Ratio: 15.77%
Additional Links:
Companies Related to NeuroDerm:

Analyst Ratings

Consensus Ratings for NeuroDerm (NASDAQ:NDRM) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.00 (54.18% upside)

Analysts' Ratings History for NeuroDerm (NASDAQ:NDRM)
Show:
DateFirmActionRatingPrice TargetDetails
12/9/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$24.00 -> $30.00View Rating Details
12/9/2016Jefferies Group LLCBoost Price TargetBuy$40.00 -> $42.00View Rating Details
5/29/2016Roth CapitalReiterated RatingBuyView Rating Details
11/10/2015Raymond James Financial, Inc.Initiated CoverageOutperform$28.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for NeuroDerm (NASDAQ:NDRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2017        
8/25/2016Q2($0.32)($0.32)ViewListenView Earnings Details
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details
3/31/2016Q4($0.29)$0.31ViewListenView Earnings Details
11/11/2015Q315($0.34)($0.49)ViewListenView Earnings Details
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details
4/2/2015($0.35)($2.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NeuroDerm (NASDAQ:NDRM)
Current Year EPS Consensus Estimate: $-1.46 EPS
Next Year EPS Consensus Estimate: $-1.73 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.29)($0.29)($0.29)
Q2 20162($0.40)($0.34)($0.37)
Q3 20162($0.40)($0.36)($0.38)
Q4 20162($0.60)($0.43)($0.52)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NeuroDerm (NASDAQ:NDRM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NeuroDerm (NASDAQ:NDRM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for NeuroDerm (NASDAQ:NDRM)
DateHeadline
News IconNeuroDerm Ltd NDRM Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:NDRM)
www.bioportfolio.com - February 21 at 6:06 PM
News IconWhat are Research Firms Saying About NeuroDerm Ltd. (NASDAQ:NDRM)? - Aiken Advocate (NASDAQ:NDRM)
aikenadvocate.com - February 17 at 5:27 PM
News IconSell-side is Weighing in on NeuroDerm Ltd. (NASDAQ:NDRM) Earnings & Targets - Aiken Advocate (NASDAQ:NDRM)
aikenadvocate.com - February 2 at 12:53 AM
News IconHow Analysts Feel About Neuroderm Ltd (NDRM) After Touching 52-Week High? - The Randolph Guide (NASDAQ:NDRM)
randolphguide.com - February 1 at 12:45 AM
globenewswire.com logoNeuroDerm Announces Extraordinary General Meeting of Shareholders - GlobeNewswire (press release) (NASDAQ:NDRM)
globenewswire.com - January 28 at 3:01 AM
finance.yahoo.com logoNeuroDerm Announces Extraordinary General Meeting of Shareholders (NASDAQ:NDRM)
finance.yahoo.com - January 26 at 11:11 PM
News IconEarnings in Full Force, Analysts Take Aim at NeuroDerm Ltd. (NASDAQ:NDRM) - Wall Street Beacon (NASDAQ:NDRM)
wsbeacon.com - January 25 at 8:50 PM
News IconNeuroDerm Ltd. (NDRM) Valuation According To Analysts - UK ... - UK Market News (NASDAQ:NDRM)
www.ukmarketnews.co.uk - January 20 at 7:35 PM
News IconSell-side Taking Aim at Shares of NeuroDerm Ltd. (NASDAQ:NDRM) - Aiken Advocate (NASDAQ:NDRM)
aikenadvocate.com - January 19 at 5:24 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: NeuroDerm Ltd. (NASDAQ:NDRM) - Wall Street Beacon (NASDAQ:NDRM)
wsbeacon.com - January 15 at 4:53 AM
News IconStock Market Drops After Trumps Biotech Pricing Comments, Impressive Come Back (NASDAQ:NDRM)
www.marketoracle.co.uk - January 13 at 5:28 AM
News IconDown Day for the Market RSS (NASDAQ:NDRM)
www.fxstreet.com - January 13 at 12:27 AM
News IconNeuroderm Ltd. (Nasdaq: NDRM) Posting Near Highs Despite Index Drop - StockNewsUnion (NASDAQ:NDRM)
stocknewsunion.com - January 12 at 7:24 PM
News IconStock Mounting Higher Mid-Session: NeuroDerm Ltd. (NASDAQ:NDRM) - Wall Street Beacon (NASDAQ:NDRM)
wsbeacon.com - January 12 at 7:24 PM
News IconShould You Sell NeuroDerm Ltd. Based On Current Broker Views? - NewsDen (NASDAQ:NDRM)
newsden.net - January 8 at 6:29 PM
nasdaq.com logo3 Reasons Why NeuroDerm (NDRM) is a Great Momentum Stock - Nasdaq (NASDAQ:NDRM)
www.nasdaq.com - January 6 at 1:17 AM
investornewswire.com logoSentiments And Ratings Alert: NeuroDerm Ltd. (NASDAQ:NDRM) - Investor Newswire (NASDAQ:NDRM)
www.investornewswire.com - January 5 at 8:16 PM
News Icon3 Reasons Why NeuroDerm (NDRM) is a Great Momentum Stock - Yahoo News (NASDAQ:NDRM)
www.yahoo.com - January 5 at 8:16 PM
finance.yahoo.com logo3 Reasons Why NeuroDerm (NDRM) is a Great Momentum Stock (NASDAQ:NDRM)
finance.yahoo.com - January 5 at 8:16 PM
finance.yahoo.com logoNeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017 (NASDAQ:NDRM)
finance.yahoo.com - January 3 at 10:41 AM
finance.yahoo.com logoWill NeuroDerm (NDRM) Continue to Surge Higher? (NASDAQ:NDRM)
finance.yahoo.com - January 3 at 10:41 AM
streetinsider.com logoNeuroDerm (NDRM) Completes Patient Enrollment, Treatment in Phase II Trial of ND0612H (NASDAQ:NDRM)
www.streetinsider.com - December 23 at 6:57 PM
finance.yahoo.com logoNeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson’s Disease (NASDAQ:NDRM)
finance.yahoo.com - December 22 at 7:05 PM
finance.yahoo.com logoNeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (NASDAQ:NDRM)
finance.yahoo.com - December 22 at 7:05 PM
News IconTale of the Tape: Technical Recap for Neuroderm Ltd. (NDRM) - StockTalk Daily (NASDAQ:NDRM)
stocktalkdaily.com - December 21 at 7:37 PM
investornewswire.com logoNeuroDerm Ltd. (NASDAQ:NDRM) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:NDRM)
www.investornewswire.com - December 21 at 7:37 PM
finance.yahoo.com logoNeuroDerm Announces Closing of a Follow-On Offering of Ordinary Shares (NASDAQ:NDRM)
finance.yahoo.com - December 12 at 6:54 PM
streetinsider.com logoJefferies Raises Price Target on NeuroDerm (NDRM) to $42 (NASDAQ:NDRM)
www.streetinsider.com - December 9 at 8:59 AM
streetinsider.com logoNeuroDerm (NDRM) Prices 4M Share Follow-on Offering for Proceeds of ~$75M (NASDAQ:NDRM)
www.streetinsider.com - December 8 at 9:48 AM
us.rd.yahoo.com logoNeuroDerm Announces Pricing of a Follow-On Offering of Ordinary Shares (NASDAQ:NDRM)
us.rd.yahoo.com - December 8 at 9:48 AM
rttnews.com logoNeuroDerm Ltd. (NDRM) Is Suring After Meeting With FDA - RTT News (NASDAQ:NDRM)
www.rttnews.com - December 7 at 9:39 AM
streetinsider.com logoNeuroDerm (NDRM) Prices 4M Share Follow-on Offering for Proceeds of ~$75M - StreetInsider.com (NASDAQ:NDRM)
www.streetinsider.com - December 7 at 9:39 AM
rttnews.com logoNeuroDerm Ltd. (NDRM) Rose Sharply Following FDA Meeting - RTT News (NASDAQ:NDRM)
www.rttnews.com - December 7 at 9:39 AM
investopedia.com logoNeuroDerm Hits 52-Week High on FDA Update (NDRM) (NASDAQ:NDRM)
www.investopedia.com - December 6 at 6:33 PM
us.rd.yahoo.com logoNeuroDerm Parkinson's Drug Gets Expedited (NDRM) (NASDAQ:NDRM)
us.rd.yahoo.com - December 6 at 6:33 PM
finance.yahoo.com logoNeuroDerm Announces Launch of a Follow-On Offering of Ordinary Shares (NASDAQ:NDRM)
finance.yahoo.com - December 6 at 6:33 PM
investing.com logo4 Stocks To Watch: CLCD, EXEL, KEM, NDRM - Investing.com (NASDAQ:NDRM)
www.investing.com - December 6 at 9:48 AM
News IconStock Jolted Higher in Mid-day Trade: NeuroDerm Ltd. (NASDAQ:NDRM) - Prospect Journal (NASDAQ:NDRM)
prospectjournal.com - December 6 at 9:48 AM
insidermonkey.com logoHedge Funds Are Crazy About Neuroderm Ltd (NDRM) - Insider Monkey (blog) (NASDAQ:NDRM)
www.insidermonkey.com - December 6 at 9:48 AM
nasdaq.com logoNeuroDerm Ltd. (NDRM) Is Suring After Meeting With FDA (NASDAQ:NDRM)
www.nasdaq.com - December 5 at 6:48 PM
finance.yahoo.com logoNeuroDerm Jumps on Critical FDA Update (NASDAQ:NDRM)
finance.yahoo.com - December 5 at 6:48 PM
News IconNeuroDerm to Discontinue ND0612H Phase III, Suspend iNDiGO After FDA Meeting (NASDAQ:NDRM)
www.biospace.com - December 5 at 10:08 AM
us.rd.yahoo.com logoHedge Funds Are Crazy About Neuroderm Ltd (NDRM) (NASDAQ:NDRM)
us.rd.yahoo.com - December 5 at 10:08 AM
us.rd.yahoo.com logoNeuroDerm to Replace Two Phase 3 Clinical Trials with Small Pharmacokinetic Trials Following FDA Meeting on ND0612 Regulatory Development (NASDAQ:NDRM)
us.rd.yahoo.com - December 5 at 10:08 AM
us.rd.yahoo.com logo6:31 am NeuroDerm announces that following its End-of-Phase 2 meeting with the FDA in late October, the Co intends to pursue a comparative bioavailability regulatory path for the Co's lead product candidate ND0612 based on comparative pharm (NASDAQ:NDRM)
us.rd.yahoo.com - December 5 at 10:08 AM
streetinsider.com logoNeuroDerm (NDRM) Announces Top-Line Data from ND0701 PK Trial; Results Comparable to Reference Drug (NASDAQ:NDRM)
www.streetinsider.com - December 3 at 5:58 PM
News IconNeuroDerm Ltd. (NDRM) – Brokers Update Their Views - NewsDen (NASDAQ:NDRM)
newsden.net - December 3 at 11:04 AM
streetinsider.com logoNeuroDerm (NDRM) Announces Top-Line Data from ND0701 PK Trial; Results Comparable to Reference Drug - StreetInsider.com (NASDAQ:NDRM)
www.streetinsider.com - December 2 at 11:26 AM
finance.yahoo.com logo7:00 am NeuroDerm announces results demonstrating ND0701 produced PK results that were comparable to those produced by the referenced drug; will initiate a follow-up comparison PK study in 1H17 (NASDAQ:NDRM)
finance.yahoo.com - December 2 at 11:26 AM
finance.yahoo.com logoNeuroDerm Announces Top-Line Results of Pilot PK Trial Comparing ND0701 with Commercial Apomorphine (NASDAQ:NDRM)
finance.yahoo.com - December 2 at 11:26 AM

Social

What is NeuroDerm's stock symbol?

NeuroDerm trades on the NASDAQ under the ticker symbol "NDRM."

Where is NeuroDerm's stock going? Where will NeuroDerm's stock price be in 2017?

3 analysts have issued 1-year target prices for NeuroDerm's stock. Their predictions range from $30.00 to $42.00. On average, they expect NeuroDerm's share price to reach $36.00 in the next year.

When will NeuroDerm announce their earnings?

NeuroDerm is scheduled to release their next quarterly earnings announcement on Wednesday, March, 29th 2017.

What are analysts saying about NeuroDerm stock?

Here are some recent quotes from research analysts about NeuroDerm stock:

  • According to Zacks Investment Research, "Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. " (2/14/2017)

  • Oppenheimer Holdings, Inc. analysts commented, "NeuroDerm reported a 4Q15 net loss/EPS of ($6.7M)/($0.31) compared to our estimates ($7.6M)/($0.35) and consensus ($6.4M)/($0.29). NeuroDerm reiterated its timeline for the initiation and expected data readouts for its multiple development programs, including top line results for the pilot PK study of ND0612H (in EU) expected 2Q16, and top line results of the Phase II efficacy trial of ND0612H in the US in 2H16. In line with previous guidance by NDRM, Cane S.p.A. has responded to the FDA letter listing manufacturing deficiencies, and so it seems that this issue has been overcome." (4/1/2016)

Who owns NeuroDerm stock?

NeuroDerm's stock is owned by a number of of institutional and retail investors. Top institutional investors include Acuta Capital Partners LLC (3.07%), Menora Mivtachim Holdings LTD. (2.66%), Franklin Resources Inc. (2.30%), Arrowpoint Asset Management LLC (1.46%), Senzar Asset Management LLC (0.86%) and Opaleye Management Inc. (0.53%).

Who sold NeuroDerm stock? Who is selling NeuroDerm stock?

NeuroDerm's stock was sold by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD. and Menta Capital LLC.

Who bought NeuroDerm stock? Who is buying NeuroDerm stock?

NeuroDerm's stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Acuta Capital Partners LLC, Senzar Asset Management LLC, Renaissance Technologies LLC, Perceptive Advisors LLC, Arrowpoint Asset Management LLC, State Street Corp and Pyrrho Capital Management LP.

How do I buy NeuroDerm stock?

Shares of NeuroDerm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NeuroDerm stock cost?

One share of NeuroDerm stock can currently be purchased for approximately $23.35.

NeuroDerm (NASDAQ:NDRM) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for NeuroDerm (NASDAQ:NDRM)

Earnings History Chart

Earnings by Quarter for NeuroDerm (NASDAQ:NDRM)

Dividend History Chart

Dividend Payments by Quarter for NeuroDerm (NASDAQ:NDRM)

Last Updated on 2/24/2017 by MarketBeat.com Staff